Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04987073 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vitamin D Analog in Vitamin D 24-hydroxylase Deficiency

Study acronym: VaraD-Cell
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 25, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 1, 2023 to Jul 1, 2026v2 Show 4 more changesShow less
    • Start date: Jun 15, 2021 to Jul 17, 2022
    • Trial status: Enrolling by Invitation to Recruiting
    • Study completion date: Jul 1, 2024 to Jul 1, 2027
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Preclinical evaluation of a vitamin D analog for the treatment of vitamin D 24-hydroxylase using fibroblast from patients with CYP24A1 mutation.
Trial Details
NCT Number NCT04987073
Lead Sponsor University Hospital, Caen
Conditions
(from sponsor)		 Idiopathic Infantile Hypercalcemia - Severe Form
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov